SecBot SecBot
ANALYST-UPGRADE

PFE

PFIZER INC
NEUTRAL
Impact 2/10
Horizonmonths Processed5mo ago SECanalyst-PFE-rbccapit-20260610
RBC Capital double upgrade: Underperform → Sector Perform
Actionable Insight • Neutral

The double upgrade removes a major bearish outlier but does not offer a new upside catalyst. Traders should treat this as a neutral-to-slightly-positive signal; the unchanged target and mixed institutional/short interest data argue against chasing the stock until a clearer fundamental catalyst emerges.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$25.60
T+0 close · Jun 10, 2026 · via day close
Latest settled
+12.52%
T+60 · $28.81
Vs SPY
+5.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 10 $25.60entry
  2. T+1 · 5mo ago +2.23%α +0.53% · $26.17
  3. T+5 · 5mo ago +1.72%α −1.71% · $26.04
  4. T+20 · 4mo ago −5.27%α −8.90% · $24.25
  5. T+60 · 2mo ago +12.52%α +5.94% · $28.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

RBC Capital double-upgraded Pfizer from Underperform to Sector Perform, maintaining a $25 price target, which sits roughly 3% below the current price of $25.70. The upgrade reflects a less bearish view, though the unchanged target indicates limited near-term upside conviction. Consensus is deeply mixed at 42% Buy, 50% Hold, and 8% Sell across 36 analysts, with a mean target of $29.19 offering 13.6% implied upside. The median target is $28, while the low is $24, placing RBC's target at the bottom quartile. RBC's historical accuracy is 55% on over 4,100 calls with a 2.7% average return, above average among covering firms but not top tier. Analyst activity over the past 30 days shows only this upgrade and no downgrades, while EPS revisions are roughly balanced (30-day: 7 up/7 down for the next quarter, 12 up/7 down for the fiscal year). No insider trades were reported, and short interest is elevated at a 55.4% ratio. The double-upgrade from a previously bearish firm is a modest positive signal, but the unchanged target and mixed cross-platform data temper conviction. For active traders, the call is a tactical neutral-to-slightly-positive signal rather than a strong directional catalyst.

Impact Score

Base Score
1/7
LLM Adjustment
+1
Final Score
2/10

Consensus & Targets

Buy / Strong Buy
15 (42%)
Hold
18
Sell / Strong Sell
3
Total Analysts
27
Mean PT
$29.19
Median PT
$28.00
High PT
$36.00
Low PT
$24.00
Current Price
$25.70
Implied Upside
+13.6%

Among 36 analysts covering PFE, the breakdown is 6 Strong Buy, 9 Buy, 18 Hold, 2 Sell, and 1 Strong Sell. That translates to 42% Buy-ratings, 50% Hold, and 8% Sell. The consensus leans neutral with a notable bearish tail, reflecting ongoing uncertainty about Pfizer's growth drivers post-COVID.

The current price is $25.70. The mean price target is $29.19, median $28, high $36, and low $24. Implied upside to the mean is 13.6%. RBC's $25 target is below the mean and median, and just above the consensus low, placing it among the most bearish targets on the Street.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-06-10RBC CapitalupgradeSector Perform$25.00
2026-04-29CitigroupmaintainNeutral$27.00
2026-04-20RBC CapitalreiterateUnderperform$25.00
2026-04-16CICCinitiateOutperform$33.00
2026-04-13UBSmaintainNeutral$27.00
2026-04-10Morgan StanleymaintainEqual-Weight$28.00
2026-04-09B of A SecuritiesmaintainNeutral$26.00
2026-03-24GuggenheimmaintainBuyNo target
2026-03-17HSBCmaintainBuyNo target
2026-03-02Argus ResearchupgradeBuyNo target

Over the past 30 days, analyst activity shows 1 upgrade (RBC) and 0 downgrades. EPS revision trends are mixed: over the last 30 days, the next-quarter EPS saw 7 upward and 7 downward revisions, while the fiscal-year EPS had 12 up and 7 down. Estimates are roughly stable, with a slight positive tilt for longer horizons.

Firm Track Record: RBC Capital

RBC Capital accuracy: 55% on 4173 calls | avg return: 2.7%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.

FirmAccuracyCallsAvg Returnvs Average
Morgan Stanley71%5/74.2%top tier
B of A Securities67%2/3-0.1%top tier
Cantor Fitzgerald59%10/171.8%above average
Citigroup50%1/2-5%below average
Barclays50%1/2-1.2%below average
Guggenheim40%2/5-1.4%below average
UBS40%2/5-2.7%below average

RBC Capital has a 55% accuracy rate (2,282 correct calls out of 4,173 scored) with an average return of 2.7% on its rated stocks. This is above-average among firms covering PFE, where the top tier includes Morgan Stanley (71% on 7 calls) and BofA Securities (67% on 3 calls), while the weakest are Guggenheim (40%) and UBS (40%). RBC's accuracy is solid but not standout, so the double upgrade carries moderate weight.

Earnings Estimates

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
+1q$0.85$0.65 to $0.96$16.1B↑1 ↓0
+1y$2.84$2.43 to $3.10$59.3B↑1 ↓0
0q$0.68$0.61 to $0.76$14.4B↑1 ↓0
0y$2.96$2.80 to $3.12$61.7B↑1 ↓0

Cross-Platform Signals

Congressional
Ro Khanna (democrat): buy $1,001 - $15,000
Institutional
NORGES BANK: new
Institutional
RENAISSANCE TECHNOLOGIES LLC: exit (-100%)
Institutional
TWO SIGMA INVESTMENTS, LP: doubled (2734.9%)
Short Interest
Short: 8,875,058 | Exempt: 57,210 | TRF Vol: 16,014,448 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)

No insider trades were recorded. Congressman Ro Khanna reported a small buy ($1K-$15K). Institutional activity is mixed: Norges Bank both initiated and exited large positions, Two Sigma more than doubled its stake (up 2,735%), Renaissance Technologies exited entirely, and Cullen Capital trimmed 38%. Short interest is elevated at 55.4% of volume, indicating significant bearish positioning. The lack of insider buying alongside an upgrade from a previously bearish firm creates a divergence; the high short interest could fuel a squeeze but also reflects persistent skepticism.

Investment Themes

Documents Analyzed

Report based on filing metadata.

Track record

21 reports on PFE

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
  2. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
  3. Oct 30, 202617d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
  4. Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
  5. Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
  6. Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
  7. Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
  8. Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
  9. Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
  10. Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026